Effects of the drug Dexmedetomidine versus propofol in reducing nausea and vomiting after gynecological surgery

Comparison of the effects of the drug Dexmedetomidine with propofol in reducing the incidence of nausea and vomiting after gynecological laparoscopic surgery

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201601081617N11

Enrollment

Registered

2016-09-22

Start date

2015-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nausea and vomiting. Postprocedural disorder of digestive system, unspecified

Interventions

Intervention 1: induction with Dexmedetomidine One microgram/kg intravenous injection in ten minutes of drug Dexmedtomidin hydrochloride of100microgram/milliliter solution (Precedex)

Prevention

induction with Dexmedetomidine One microgram/kg intravenous injection in ten minutes of drug Dexmedtomidin hydrochloride of100microgram/milliliter solution (Precedex)

induction with propofol

Eligibility

Sex/Gender

Female

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Female gender, undergoing elective gynecologic laparoscopic surgery , fasting for eight hours, consent to participate in the study Exclusion criteria: duration of operation more than two hours, the use of antiemetics

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Nausea. Timepoint: thirty minutes after consciousness. Method of measurement: questionnaire.;Vomiting. Timepoint: thirty minutes after consciousness. Method of measurement: questionnaire.	—

Secondary

Measure	Time frame
----. Timepoint: ---. Method of measurement: ----.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAida Lahoorpour

Imam Reza Hospital

mchoobsaz@kums.ac.ir+98 83 3724 6708

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026